literature

HIV mutation literature information.

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.

PMID: 33941212 2021 AIDS research and therapy

Method: Patients with the following baseline mutations associated with reduced susceptibility to DTG: T66K, E92Q, G118R, E138 K/A/T, G140 S/A/C, Q148 H/R/K, N155H and R263K were excluded.

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.

PMID: 33807382 2021 Viruses

Method: The mutations of interest included: T66A/I/K, E92Q, G118R, E138K/A/T, G140S/A/C, Y143R/C/H, S147G, Q148H/R/K, N155H and R263K.

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.

PMID: 33369017 2021 HIV medicine

Method: INSTI mutations, which are not included on this list, were defined as those on the Stanford HIVdb surveillance DRM list, namely T66AIK, E92Q, F121Y, G140ACS, Y143CHR, S147G, Q148HKR and N155HS.

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.

PMID: 32379830 2020 PloS one

Result: Calculation of the covariance matrix values after diagonalization showed a significant increase for the G140S system (18.33 nm) compared to the other three systems WT, E92Q and Y143R each having 9.58 nm, 8.98 nm and 10.41 nm lower values, respectively.

Result: Distance analysis indicated a smaller average distance of 0.21 +- 0.01 nm and 0.22 +- 0.01 nm between the WT, Y143R MG ion and drug DTG systems compared to E92Q and G140S each having a distance of 0.41 +- 0.04 nm, 0.99 +- 0.20 nm, respectively.

Result: On the other hand, the E92Q system showed interactions with one of the active site residues (D116) but no MG ionic interactions (Table 3).

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

PMID: 31617907 2020 The Journal of antimicrobial chemotherapy

Abstract: Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K.

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

PMID: 31965175 2020 The Journal of infectious diseases

Abstract: In IN, 11 nonpolymorphic TSMs occurred in >=4 persons: Q91R, E92AQ, T97A, G140S, Y143G, Q148R, A153G, N155H, H156R, R231 5-amino acid insertions.

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: E92Q

Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.

PMID: 32106437 2020 International journal of molecular sciences

Discussion: The aa substitutions E92Q, S119R, E138A, Y143R, G148H/R, and S230R/N are more prevalent in subtype-B than in non-B subtypes, whereas mutations such as L74I/M, T97A, L101I, E157Q, T214A, and V201I are more prevalent in non-B subtypes compared to HIV-1 subtype B.

Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.

PMID: 33014372 2020 SAGE open medicine

Table: E92Q

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.

PMID: 31037930 2019 Revista espanola de quimioterapia

Table: E92Q